These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 20000887)

  • 1. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
    Bazzoli C; Jullien V; Le Tiec C; Rey E; Mentré F; Taburet AM
    Clin Pharmacokinet; 2010; 49(1):17-45. PubMed ID: 20000887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular pharmacokinetics of antiretroviral agents.
    Owen A; Khoo SH
    J HIV Ther; 2004 Nov; 9(4):97-101. PubMed ID: 15731742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.
    Fraaij PL; van Kampen JJ; Burger DM; de Groot R
    Clin Pharmacokinet; 2005; 44(9):935-56. PubMed ID: 16122281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 antiretroviral resistance: scientific principles and clinical applications.
    Tang MW; Shafer RW
    Drugs; 2012 Jun; 72(9):e1-25. PubMed ID: 22686620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
    Fletcher CV; Kawle SP; Kakuda TN; Anderson PL; Weller D; Bushman LR; Brundage RC; Remmel RP
    AIDS; 2000 Sep; 14(14):2137-44. PubMed ID: 11061655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
    Torres HA; Rallapalli V; Saxena A; Granwehr BP; Viola GM; Ariza-Heredia E; Adachi JA; Chemaly RF; Marfatia R; Jiang Y; Mahale P; Kyvernitakis A; Fanale MA; Mulanovich V
    Clin Microbiol Infect; 2014 Oct; 20(10):O672-9. PubMed ID: 24529214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
    Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
    Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host factors and efficacy of antiretroviral treatment.
    Turriziani O; Antonelli G
    New Microbiol; 2004 Apr; 27(2 Suppl 1):63-9. PubMed ID: 15646066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of intracellular triphosphate metabolites of antiretroviral agents in peripheral blood mononuclear cells (PBMCs) and corresponding cell count determinations: review of current methods and challenges.
    Xiao D; Ling KHJ; Custodio J; Majeed SR; Tarnowski T
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):781-802. PubMed ID: 30010446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.
    Anderson PL; Kakuda TN; Kawle S; Fletcher CV
    AIDS; 2003 Oct; 17(15):2159-68. PubMed ID: 14523272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
    Piliero PJ
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.
    Hodel EM; Marzolini C; Waitt C; Rakhmanina N
    Curr Pharm Des; 2019; 25(5):556-576. PubMed ID: 30894103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.